公开(公告)号：US11040111B2

公开(公告)日：2021-06-22

申请号：US16111242

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Steven R Roffler ,  Tian-Lu Cheng ,  Chien-Han Kao ,  Bing-Mae Chen ,  Yu-Cheng Su ,  Hsin-Yi Tung ,  Kuo-Hsiang Chuang

IPC: C07K16/00 ,  A61K47/68 ,  C07K16/44 ,  C07K16/32 ,  C07K16/30 ,  C07K16/28 ,  A61K49/00 ,  A61K47/69 ,  A61K39/395 ,  A61K47/60 ,  A61K39/00

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US20210292438A1

公开(公告)日：2021-09-23

申请号：US17340102

申请日：2021-06-07

Applicant: ACADEMIA SINICA

Inventor： Steve ROFFLER ,  Tian-Lu Cheng ,  Yu-Cheng Su ,  Kuo-Hsiang Chuang

IPC: C07K16/44 ,  A61K47/60 ,  A61K47/69 ,  A61P35/00 ,  A61K31/55 ,  A61K31/704 ,  A61K51/06 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  G01N33/574

Abstract: A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also disclosed is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. Further disclosed is a method for diagnosing a cell-mediated disorder by administering a PEG engager followed by a PEGylated diagnostic agent.

公开(公告)号：US20150377887A1

公开(公告)日：2015-12-31

申请号：US14769294

申请日：2014-02-27

Applicant: Yu-cheng SU ,  Steve R. ROFFLER ,  ACADEMIA SINICA

Inventor： Yu-Cheng Su ,  Steve R. ROFFLER

IPC: G01N33/577 ,  C07K16/40 ,  C07K16/44 ,  G01N33/68 ,  G01N33/50

CPC classification number: G01N33/577 ,  C07K16/00 ,  C07K16/40 ,  C07K16/44 ,  C07K2317/14 ,  G01N33/5008 ,  G01N33/6854

Abstract: This disclosure relates to a method to mimicking the germinal center reaction to generate antibodies with altered binding properties or increased affinity directly in hybridomas. To allow convenient and rapid affinity maturation of antibodies, a controllable activation-induced cytidine deaminase (AID) expression system to induce somatic hypermutation in hybridomas is developed. Selection of high affinity antibodies is achieved by fluorescence-activated cell sorting of hybridomas that preferentially bind fluorescence-labeled antigens. The disclosure also relates to de novo generation of hybridomas with tunable antibody affinity by generating myeloma fusion partners with controllable AID expression.

Abstract translation: 本公开涉及模拟生发中心反应以产生具有改变的结合特性或直接在杂交瘤中增加的亲和力的抗体的方法。 为了允许抗体的方便和快速的亲和力成熟，开发了可控的活化诱导的胞苷脱氨酶（AID）表达系统以诱导杂交瘤中的体细胞超突变。 通过优先结合荧光标记的抗原的杂交瘤的荧光激活细胞分选来实现高亲和力抗体的选择。 本公开还涉及通过产生具有可控AID表达的骨髓瘤融合配偶体从而产生具有可调节抗体亲和力的杂交瘤。

公开(公告)号：US11369690B2

公开(公告)日：2022-06-28

申请号：US16111250

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Steven R Roffler ,  Tian-Lu Cheng ,  Chien-Han Kao ,  Bing-Mae Chen ,  Yu-Cheng Su ,  Hsin-Yi Tung ,  Kuo-Hsiang Chuang

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32 ,  A61K39/395 ,  C07K16/28 ,  C07K16/26 ,  A61K47/14 ,  A61K47/69 ,  A61K45/06

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US10188742B2

公开(公告)日：2019-01-29

申请号：US15123243

申请日：2015-03-02

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Steven R Roffler ,  Tian-Lu Cheng ,  Chien-Han Kao ,  Bing-Mae Chen ,  Yu-Cheng Su ,  Hsin-Yi Tung ,  Kuo-Hsiang Chuang

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/48 ,  A61K49/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/44 ,  A61K47/68

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.